Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat
Sandoz Enbrel Ruling Leads Company To Chop Asset
Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.
